TSHA — Taysha Gene Therapies Income Statement
0.000.00%
Last trade - 00:00- $1.13bn
- $885.28m
- $8.33m
Annual income statement for Taysha Gene Therapies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 2.5 | 15.5 | 8.33 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 43 | 173 | 165 | 89.3 | 99.8 |
| Operating Profit | -43 | -173 | -162 | -73.8 | -91.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -60 | -175 | -166 | -112 | -89.3 |
| Net Income After Taxes | -60 | -175 | -166 | -112 | -89.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -60 | -175 | -166 | -112 | -89.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -60 | -175 | -166 | -112 | -89.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.74 | -4.64 | -2.95 | -0.94 | -0.338 |